Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Lystek International Corp. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is being handled by 1 distinct examiner, indicating a highly concentrated prosecution focus for the company's current portfolio. The prosecution activity is localized within 1 distinct art unit, which suggests a specific technical niche for the pending application. This narrow distribution allows for a focused legal strategy but also means the portfolio lacks examiner or art unit diversity.
The busiest examiner identified in the portfolio is EPSTEIN, TODD MATTHEW, who is responsible for 1 busiest examiner pending office action. This individual accounts for all of the company's current pending office actions. For practitioners, this concentration means that the outcome of the portfolio's immediate prosecution depends entirely on the interactions with this single examiner and the specific standards of the associated art unit. Success in this technology area requires navigating the specific requirements of this examiner, as there are no other active matters to provide comparative insights or alternative paths to allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EPSTEIN, TODD MATTHEW | 1 | 60.8% | +43.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18594264 | METHOD OF TREATMENT OF ANIMAL MANURE FOR BIOGAS PRODUCTION | EPSTEIN, TODD MATTHEW | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18594264 | METHOD OF TREATMENT OF ANIMAL MANURE FOR BIOGAS PRODUCTION | EPSTEIN, TODD MATTHEW | 1652 | §103 | Non-Final OA | — | Pending | Mar 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLystek International Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Todd Matthew Epstein has the most, with 1 of Lystek International Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
